Lipophilic active oral film formulation and method of making the same
Disclosed is a description and methods for formulating oral films containing lipophilic active ingredient(s), more particularly lipophilic active having a positive log P. The method involves dispersing the lipophilic active(s) in a carrier oil and uniformly distributing them as emulsified oil droplets into a polymer matrix. The methods reported here produce oral films containing a stable emulsion with up to 40% oil phase. The oil phase consists of the carrier oil and lipophilic active(s). This offers the possibility to enhance the amount of lipophilic actives to be included in the film formulation while preserving the film characteristics. The resulting oral films offer a standardized dosage form for lipophilic actives as well as easier and more convenient administration, transportation, handling, and storage.
1. An emulsion based oral film dosage form for human or animal administration comprising:
a. an unbuffered oil in water emulsion based continuously cast film layer comprising:
i. a carrier oil;
ii. an amphiphilic pharmaceutical active; and
iii. a water soluble film forming polymer;
b. wherein the amphiphilic pharmaceutical active exhibits surfactant properties;
c. wherein the combined quantity of carrier oil and amphiphilic pharmaceutical active is more than about 20% (wt/wt) of the oral film dosage form; and
d. wherein the film layer has a contact angle of less than 90 degrees.
2. The oral film dosage form of claim 1 , wherein the amphiphilic pharmaceutical active is Montelukast.
3. The oral film dosage form of claim 2 , further comprising a chelating agent.
4. An oral film dosage form for human or animal administration comprising:
a film layer comprising:
a. a lipophilic active;
b. a carrier oil;
c. a water soluble film forming polymer;
wherein the film layer has a surface pH equal or lower than 4 and
wherein the film layer has a contact angle of less than 90 degrees.
5. The oral film dosage form of claim 4 , wherein the combined quantity of carrier oil and lipophilic active is more than about 25% (wt/wt) of the oral film dosage form.
6. The oral film dosage form of claim 4 , wherein the combined quantity of carrier oil and lipophilic active is more than about 40% (wt/wt) of the oral film dosage form.
7. The oral film dosage form of claim 4 , wherein the film layer further comprises a viscosity modifier.
8. The oral film dosage form of claim 4 , wherein the film layer retains at least 95% of the oil and lipophilic active.
9. The oral film dosage form of claim 4 , wherein the contact angle of the film is below 80 degrees.
10. The oral film dosage form of claim 8 , wherein the contact angle of the film is below 70 degrees.
11. The oral film dosage form of claim 4 , wherein the contact angle of the film is below 60 degrees.
12. The oral film dosage form of claim 4 , wherein the lipophilic active is THC and the carrier oil is MCT oil.
13. The oral film dosage form of claim 4 , further comprising pectin in the film layer comprising the lipophilic active or in a one or more protective layers joined to the film layer comprising the lipophilic active, the pectin being present in an amount effective to provide targeted enteric delivery of the lipophilic active to the colon or large intestine upon administration.
14. An emulsion based edible oral film dosage form for human or animal administration comprising:
a. a film layer comprising
i. a lipophilic active;
ii. a carrier oil; and
iii. a water soluble film forming polymer;
wherein all components are food grade; and
wherein the film layer has a surface pH equal or lower than 4 and
wherein the film layer has a contact angle of less than 90 degrees.
15. The emulsion based edible oral film dosage form of claim 14 wherein the polymer is HPMC.
16. The emulsion based edible oral film dosage form of claim 15 wherein the emulsion is stabilized by a polymer and where the oral film further comprises a cannabinoid.
17. The emulsion based edible oral film dosage form of claim 14 further comprising two protective layers, each of which is joined to one of opposite sides of the film layer, the protective layers each comprising a basifying agent or base buffering component that maintains a basic pH environment when the dosage form is orally administered.
18. The oral film dosage form of claim 17 wherein the combined quantity of carrier oil and lipophilic active is more than about 40% (wt/wt) of the oral film dosage form.
19. The oral film dosage form of claim 1 , wherein the carrier oil is present in an amount of 10-40% w/w of the oral film dosage form.
20. The oral film dosage form of claim 4 , wherein the carrier oil is present in an amount of 10-40% w/w of the oral film dosage form.